

MARCH 2023 | EDITION #3



Updates and Accolades

- Our first webinar took place on January 24, 2023: "DeltaT1 Maps Defined with Examples of Clinical Utility" by Dr. Kathleen Schmainda, PhD. It was an enormous success allowing attendees an interactive Q&A session. [View webinar video here](#)
 - In January, a paper was published describing the use of diffusion imaging to non-invasively differentiate benign from malignant breast cancer. These parameters are currently available in IB's Diffusion module (ADC, IVIM, Alpha, DDC). [View here](#)
 - Dr. Joseph A. Bovi, MD, Professor at the Department of Radiation Oncology, Froedtert Hospital & The Medical College of Wisconsin, presented at the 2023 Advances in Musculoskeletal Oncology Symposium in Miami, FL. He described the success of the metastases management mobile app, IB Nimble.
 - Using IB Neuro (rCBV) is important for further stratifying patient response in those that do not show T1+C progression. Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudo-response in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625 [View here](#)
 - Wake Forest School of Medicine found including radiologists in radiotherapy prep bolsters quality of care. "Many radiation oncologists are not formally trained in image interpretation." This highlights the critical need for proven and accurate imaging in all cancer assessments. [View here](#)
 - A report of the RANO resect group describes prognostic validation of a new classification system for the extent of resection in glioblastoma. [View here](#)
- IB Delta T1 maps make residual tumor volume (RTV) measurements easy by:**
- **eliminating confounding pre-contrast "bright T1" signal**
 - **enabling objective determination of contrast-enhancing volume**
 - **enabling quantitative determination of RTV.**
- IB provided training for MR Technologists at two sites to perform the Delta T1 volume measurements for pre- and post-surgical assessment of resection extent.



Dr. Joseph A. Bovi presenting the 2023 Advances in Musculoskeletal Oncology Symposium

UPCOMING SHOWS


Imaging Biometrics will be exhibiting in booth #103 at this year's ASNR meeting where Dr. Kathleen Schmainda will be presenting "State of the Art MR Perfusion Imaging in Brain Tumors." Contact us and schedule a meeting: info@imagingbiometrics.com



Imaging Biometrics continues to pursue robust AI solutions to automate image segmentation with an accepted paper to the upcoming **ASNR meeting in Chicago (Apr 29 – May 3)** – presenting author Jay Urbain, PhD.

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider, Blackford Analysis Ltd. [Learn more](#)

IB'S TOOLS ARE AVAILABLE ON THE BLACKFORD AND BAYER CALANTIC PLATFORMS.



Exciting news: The FDA granted Orphan Drug Designation status to IB for the oral agent Gallium Maltolate, currently in clinical trial at the Medical College of Wisconsin. The clinical trial of Gallium Maltolate for the treatment of recurring Glioblastoma is open for enrollment. [Learn more](#)

Meet Linda Herman

EMPLOYEE SPOTLIGHT

Linda is our Client Relations Manager. She came to us from GE Healthcare where she retired as a Clinical Imaging Specialist for SAVI (Surgical and Vascular Imaging). Linda lives in Camas, WA, and is also the PKD Connect Ambassador for the Polycystic Kidney Disease Foundation in the Pacific NW. "When not working, I most enjoy spending time with my family, reading, and hiking. I'm grateful to work with such an amazing group of professionals at IB!"




Being Deployed

IB NIMBLE

IB Nimble, a handheld app designed by Dr. Joe Bovi at The Medical College of Wisconsin, is no longer specific to metastatic tumors! The same framework used to facilitate secure, virtual, and real-time discussions among multi-disciplinary treatment teams for metastatic brain tumor patients is being prepared to benefit other disease groups. Contact IB to learn how IB Nimble can be deployed in your institution.

[IB NIMBLE - Virtual Collaboration for treatment optimization](#)

IB USER'S GROUP



On April 11, at Noon CDT, Dr. Michael Iv, MD will present a webinar titled "Clinical Advances of Perfusion MRI in the Current Neuro-oncology Landscape." Dr. Iv is the Clinical Associate Professor of Radiology and currently serves as the Director of Brain Tumor Imaging at the Stanford Brain Tumor Center.

REGISTER NOW

[click here to register for our upcoming webinar](#)

FOLLOW US ON

 https://twitter.com/iqai_ib

 <https://www.linkedin.com/company/imaging-biometrics-llc>

13416 Watertown Plank Road

Suite 260 | Elm Grove, WI 53122

+1.262.439.8252